FDA
approval
· 2022-12-16
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
Summary
FDA approved a supplemental application for a generic buprenorphine and naloxone product from Lannett Company, expanding access to treatment for opioid use diso…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)